Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.
Meitheal Pharmaceuticals has ushered in what it believes is a “pivotal moment,” picking up its fifth biosimilar product and the first one on the market after gaining the exclusive US commercial rights to Coherus BioSciences’ Yusimry (adalimumab-aqvh) biosimilar to Humira.
The US-based injectables specialist’s parent company, Hong Kong King-Friend (HKF), has paid $40m upfront to Coherus for the worldwide rights...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
